Article Information
History
- September 26, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Victoria Northrup1,2,6,
- Ashley L. Eadie1,2,6,
- Victoria L. Nelson1,2,6,
- Kenneth D’Souza1,2,3,6,
- Ansar Hassan3,6,
- Thomas Pulinilkunnil2,4,6,
- Petra Kienesberger2,4,6,
- Jean-Francois Légaré3,6,
- Jeremy A. Simpson5,6 and
- Keith R. Brunt1,2,3,6,†
- 1Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada
- 2Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada
- 3Departments of Cardiology & Cardiac Surgery, New Brunswick Heart Center, Saint John Regional Hospital, Saint John, New Brunswick, Canada
- 4Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada
- 5Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada
- 6IMPART investigator team Canada (https://impart.team/)
- ↵†Corresponding Author: Dr. Keith R. Brunt, 100 Tucker Park Road, Box 5050, Saint John, NB, Canada, E2L 4L5, 1-(506)-636-6974, keith.brunt{at}dal.ca, @prof_brunt (social media)
Posted September 26, 2024.
Erythropoietin single nucleotide polymorphisms are associated with anemia and dyslipidemia in a cardiovascular disease population
